Cend Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 5

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10M

Cend Therapeutics General Information

Description

Developer of a tumor-targeted tissue penetration drug intended to treat solid tumor cancers. The company offers technologies to enable more effective tumor-targeted, tissue-penetrating delivery of nucleic acid-based drugs, including targeted nanoparticle technologies to help protect and target delivery, providing clinicians with more effective treatment of difficult-to-treat solid tumor cancers.

Contact Information

Website
www.cendrx.com
Formerly Known As
DrugCendR
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 12544 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 12544 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cend Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 15-Sep-2022 $10M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 17-Sep-2020 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 27-Mar-2019 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 25-May-2018 $1M $2M Completed Clinical Trials - Phase 2
1. Capitalization 01-Jan-2015 $1M $1M Completed Startup
To view Cend Therapeutics’s complete valuation and funding history, request access »

Cend Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 371,396 $0.000010 $2.96 $2.96 1x $2.96 8.74%
To view Cend Therapeutics’s complete cap table history, request access »

Cend Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a tumor-targeted tissue penetration drug intended to treat solid tumor cancers. The company offers technolo
Drug Discovery
San Diego, CA
5 As of 2022

Copenhagen, Denmark
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cend Therapeutics Competitors (47)

One of Cend Therapeutics’s 47 competitors is Antag Therapeutics, a Venture Capital-Backed company based in Copenhagen, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Antag Therapeutics Venture Capital-Backed Copenhagen, Denmark
PepGen Formerly VC-backed Boston, MA
Apeptico Formerly VC-backed Vienna, Austria
Oncorus Formerly VC-backed Andover, MA
MBX Biosciences Formerly VC-backed Carmel, IN
You’re viewing 5 of 47 competitors. Get the full list »

Cend Therapeutics Patents

Cend Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200282013-A1 Low-dose cytokine co-administered with irgd for treating cancer Inactive 08-Mar-2019
WO-2020185624-A1 Low-dose cytokine co-administered with irgd for treating cancer Inactive 08-Mar-2019

Cend Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cend Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kyoto University Innovation Capital Venture Capital Minority
To view Cend Therapeutics’s complete investors history, request access »

Cend Therapeutics Acquisitions (1)

Cend Therapeutics’s most recent deal was a Merger/Acquisition with Impilo Therapeutics. The deal was made on 21-Sep-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Impilo Therapeutics 21-Sep-2020 Merger/Acquisition Drug Discovery
To view Cend Therapeutics’s complete acquisitions history, request access »

Cend Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Impilo Therapeutics San Diego, CA 2019

Cend Therapeutics FAQs

  • When was Cend Therapeutics founded?

    Cend Therapeutics was founded in 2015.

  • Where is Cend Therapeutics headquartered?

    Cend Therapeutics is headquartered in San Diego, CA.

  • What is the size of Cend Therapeutics?

    Cend Therapeutics has 5 total employees.

  • What industry is Cend Therapeutics in?

    Cend Therapeutics’s primary industry is Drug Discovery.

  • Is Cend Therapeutics a private or public company?

    Cend Therapeutics is a Private company.

  • What is the current valuation of Cend Therapeutics?

    The current valuation of Cend Therapeutics is .

  • What is Cend Therapeutics’s current revenue?

    The current revenue for Cend Therapeutics is .

  • How much funding has Cend Therapeutics raised over time?

    Cend Therapeutics has raised $11.1M.

  • Who are Cend Therapeutics’s investors?

    Kyoto University Innovation Capital has invested in Cend Therapeutics.

  • Who are Cend Therapeutics’s competitors?

    Antag Therapeutics, PepGen, Apeptico, Oncorus, and MBX Biosciences are some of the 47 competitors of Cend Therapeutics.

  • When was Cend Therapeutics acquired?

    Cend Therapeutics was acquired on 15-Sep-2022.

  • Who acquired Cend Therapeutics?

    Cend Therapeutics was acquired by Lisata Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process